

NEWSLETTER
ISSUE NOVEMBER 2025

LONGEVITY & ANTI-AGING STARTUPS



03

The Healthspan Revolution



04

Ageless Ambitions:
The Human Quest to Outrun Time



06

Theme Article:
What is Longevity and Anti-Aging Biotech?




12

Funding News & Updates



13

Book Review



14

Terminologies

THE HEALTHSPAN REVOLUTION

The longevity and anti-aging sector stands at a remarkable inflection point. What was once dismissed as fringe science has evolved into one of the most compelling investment opportunities of our generation, with the potential to address an \$8 billion market—representing every person on Earth.

We are witnessing a fundamental shift in how humanity approaches aging. Rather than accepting decline as inevitable, scientists and entrepreneurs are now treating aging as a modifiable condition—one that can be slowed, halted, or even reversed through therapeutic intervention. This represents a paradigm shift from reactive disease management to proactive healthspan extension, where the focus is not merely on adding years to life but adding healthy, productive years.

For investors, the opportunity is unprecedented. The global longevity biotech market reached \$8.74 billion in 2025 and is projected to surge to \$22.97 billion by 2034, growing at a compound annual growth rate of 12.84%. Total financing in the longevity sector reached \$8.49 billion across 331 deals in 2024, marking a 220% increase from 2023. Investment in longevity startups has grown fivefold since 2015, exceeding \$5 billion in 2023.

For startups, the landscape has never been more fertile. The number of longevity-focused biotech companies has exploded from just 50 in 2015 to over 250 in 2024. These companies are pioneering breakthrough approaches including cellular rejuvenation, senolytics, epigenetic reprogramming, AI-driven drug discovery, and gene editing—



Written by,

CA MAYANK DESAI

**Co-Founder, Unisync Angels
Partner, Y.B. Desai & Associates**

all aimed at targeting the root causes of aging rather than merely treating symptoms.

The convergence of advanced biotechnology, artificial intelligence, massive datasets, and computational power has created an unprecedented capability to understand and intervene in the aging process. Major pharmaceutical companies are taking notice—Eli Lilly's investment in NewLimit signals that longevity is transitioning from moonshot science to mainstream therapeutic development.

The demographic imperative is clear: by 2050, the global population over 60 will reach 2.1 billion, double today's number. This aging tsunami presents not a crisis but an opportunity—to extend the years humans live in good health, reduce the burden of age-related diseases, and transform healthcare from disease management to prevention and optimization.

This newsletter explores the dynamic longevity ecosystem, examining global and Indian perspectives, highlighting pioneering startups, and providing insights into funding trends and business models that are reshaping how we think about aging, health, and human potential.



AGELESS AMBITIONS: THE HUMAN QUEST TO OUTFRAN TIME

There was a time when living past forty was a miracle. When kings feared infections more than rebellions, and childbirth was a gamble, not a guarantee.

But look around today - humanity has stretched its lease on life. From an average age of 30 in the 19th century to over 75 in the 21st, we've doubled our stay on Earth, thanks to the miracles of medicine, sanitation, and science. Antibiotics replaced prayers, vaccines outwitted viruses, and surgeons became sculptors of destiny.

Yet the human heart is a restless tenant, it never wants to leave the house it calls home.

We are not just fighting diseases anymore; we are waging war against time itself. From cryotherapy chambers and gene editing to NAD boosters and AI-driven diagnostics, we are decoding the body like a machine that can be reprogrammed, repaired, and, someday, rebooted.

THE AGELESS DREAM

Aging has become humanity's final frontier - the Everest we all want to summit without falling off the other side. Elon Musk dreams of colonizing Mars; others dream of colonizing tomorrow.

Biotech pioneers like David Sinclair talk of "reversing" aging, not just delaying it. Stem cells are being trained to remember youth. DNA is being edited to forget decay. The human body, once a story with a tragic ending, may soon be rewritten as a series of sequels.



Written by,

MR. KASHYAP PANDYA

**Co-Founder, Unisync Angels
Director, Syncoro Ventures**

In the quiet corners of Silicon Valley, billionaires are funding labs that promise immortality in subscription form. The fountain of youth might not be found in a jungle - it may arrive as a monthly auto-debit on your credit card.

OUR CINEMATIC FASCINATION

Hollywood has long flirted with immortality. From *The Curious Case of Benjamin Button* to *In Time*, from *Lucy* to *Altered Carbon*, we've seen versions of ourselves bending the rules of mortality. Each film a reflection of the same haunting question: What if death was just a design flaw?

Cryogenic labs today already house frozen dreamers - bodies preserved in liquid nitrogen, waiting for a future that remembers how to restart them. It sounds like *Interstellar* meets *Black Mirror*, yet the day isn't far when these "sleeping humans" might awaken to a new dawn, revived not by God, but by algorithms.

WHEN HUMANS MEET THEIR MIRRORS

But as we chase longevity, we're also creating something eerily similar - machines that don't age at all. Humanoids now walk, talk, and emote like us. Sifra smiles. Ameca converses.

And soon, your office colleague might have perfect attendance because she doesn't need sleep or coffee.

The line between man and machine is blurring. In the near future, we may not be able to tell who's human and who's hardware. Both will be ageless - one by code, one by choice.

As Arthur C. Clarke said, "Any sufficiently advanced technology is indistinguishable from magic." And perhaps, immortality will be our final act of magic - our way of saying to Time, "You can't fire me. I quit."

THE FINAL REFLECTION

In chasing longevity, we are not merely extending life - we are extending meaning. We want to see the next sunrise, the next invention, the next version of ourselves. Because deep down, humanity's greatest fear isn't death - it's missing out on what happens next.

Maybe one day, like in the movies, we will wake up after centuries of sleep, our memories uploaded, our bodies restored, our souls rebooted. And as we step into a world where humans and humanoids coexist - both timeless, both sentient - we might finally realize that immortality was never about living forever. It was about making every moment worth reliving.

TERMINOLOGIES

1

Healthspan:

The period of life spent in good health, free from chronic disease or disability.

Biological Age:

A measure of how old your cells or body functions biologically, versus your chronological age.

2

3

Geroscience:

The study of the biological mechanisms of ageing and how to slow or reverse them.

Anti-Ageing Therapy:

Interventions aimed at delaying the onset of ageing-related diseases.

4



WHAT IS LONGEVITY AND ANTI-AGING BIOTECH?

Longevity and anti-aging biotech represents a transformative sector within healthcare focused on extending human healthspan—the period of life spent in good health—by targeting the fundamental biological mechanisms that drive aging. Unlike traditional medicine that treats diseases after they manifest, longevity biotech aims to address aging itself as the primary risk factor for chronic conditions including cancer, cardiovascular disease, neurodegeneration, and metabolic disorders.

CORE APPROACHES AND TECHNOLOGIES

Cellular Rejuvenation and Reprogramming: Companies like Altos Labs (\$3.3 billion raised) are pioneering cellular rejuvenation using Yamanaka factors—proteins that can reprogram adult cells to younger, more resilient states. This approach aims to restore cellular function at its most fundamental level.

Senolytics: These therapeutics selectively eliminate senescent "zombie" cells that accumulate with age and drive inflammation, tissue dysfunction, and disease. Unity Biotechnology has advanced senolytic drug candidates to Phase 2 clinical trials for conditions including diabetic macular edema.

Epigenetic Reprogramming: NewLimit (\$130 million Series B) is developing medicines that reprogram the epigenome to restore youthful gene expression patterns in aged cells.

Their prototype liver therapies have demonstrated the ability to make old cells behave like young ones.

AI-Driven Drug Discovery: Insilico Medicine uses artificial intelligence and deep learning to identify therapeutic targets implicated in both aging and age-related diseases, dramatically accelerating the drug discovery timeline. The company has advanced AI-discovered drug candidates into Phase 2 clinical trials.

Gene Editing and Therapy: CRISPR applications for longevity have seen a 12-fold increase in research funding since 2016, enabling precise targeting of age-related genes and DNA repair mechanisms.

Microbiome Optimization: Companies are developing diagnostic and intervention strategies that personalize gut health to mitigate age-related decline in immunity, metabolism, and inflammation.

Key Therapeutic Areas:


The longevity market encompasses anti-aging supplements, regenerative medicine, cellular therapies, gene therapies, senolytics, stem cell treatments, and nutraceuticals. Applications span preventive healthcare, chronic disease management, fitness and wellness, and mental health enhancement.

GLOBAL VIEW: THE LONGEVITY REVOLUTION GOES MAINSTREAM

Market Size and Growth Trajectory:

Anti Aging Market

Size, by Product Type, 2024-2034 (US\$ Billion)



ANTI-AGING MARKET: 2024-2034 GROWTH OVERVIEW

The global anti-aging market is experiencing explosive expansion, growing from \$77.9 billion in 2024 to \$159.0 billion by 2034—a 7.3% compound annual growth rate representing over 100% market growth.

Product category breakdown reveals distinct growth patterns:


Anti-wrinkle creams and moisturizers remain the dominant segment, doubling from \$20.7 billion to \$41.9 billion, driven by consumer accessibility and proven efficacy. Serums and hair oils emerge as premium categories, each growing over 110% as consumers seek targeted, efficacious solutions.

Injectables represent the fastest-growing segment, expanding 130% to \$29.0 billion, reflecting accelerating adoption of minimally invasive procedures and democratization of access. Anti-aging shampoos grow 116%, while medical devices show modest 0.9% growth, indicating market maturation.

This expansion reflects unprecedented global aging, rising disposable incomes particularly in Asia-Pacific, and consumer preference for preventive rather than corrective approaches to aging. Success requires category-specific differentiation and strategic positioning across price points.

Anti Aging Market

Share, By Treatment Type, 2024 (%)



ANTI-AGING MARKET: TREATMENT TYPE DISTRIBUTION & GROWTH (2024)

The anti-aging market, valued at \$77.86 billion in 2024, demonstrates a distinct segmentation by treatment modality, with topical treatments commanding 42.5% market share—the dominant treatment category.

Market composition by treatment type:

Topical Treatments (\$33.1 billion) lead with 42.5% share, encompassing creams, serums, oils, and skincare formulations offering accessibility and affordability for mass-market penetration.

Injectables capture substantial share through botulinum toxins and dermal fillers, representing the high-growth professional treatment segment.


Laser Treatments constitute a significant middle segment, offering clinical-grade non-invasive rejuvenation through professional delivery channels.

Surgical Procedures represent invasive interventions like facelifts and brow lifts, serving premium consumer segments.

The market projects 7.4% compound annual growth rate through 2034, driven by aging demographics, procedure democratization, and consumer acceptance of professional anti-aging interventions. Topical treatments' dominance reflects cost-effectiveness and self-administered convenience, while procedure-based segments (injectables, laser, surgical) demonstrate accelerating adoption among affluent consumers seeking dramatic results.

Anti Aging Market

Regional Analysis in 2024



Asia-Pacific is expected to hold the Largest Anti Aging Market Share

ANTI-AGING MARKET: REGIONAL ANALYSIS 2024

The global anti-aging market demonstrates stark geographic disparities, with Asia-Pacific (APAC) commanding \$33.87 billion—the largest regional market and poised for sustained leadership.

Regional market dynamics:

Asia-Pacific (\$33.87 Bn) dominates due to massive population base, rapid economic development, affluent consumer segments, beauty consciousness, and underpenetrated markets creating explosive growth potential. China, India, Japan, and South Korea drive this segment.

North America represents mature, saturated market with established consumer adoption, premium pricing, and focus on innovative procedures and advanced treatments.

Europe maintains substantial presence through high consumer spending, strong regulatory frameworks, and established aesthetic medicine infrastructure.

Middle East & Africa (MEA) represents emerging market with growing luxury wellness sector and increasing disposable incomes among affluent segments.

Latin America captures regional demand from upper-middle-class consumers seeking accessible anti-aging solutions.


NUMBER OF COMPANIES AND ECOSYSTEM SCALE:

The longevity ecosystem has matured rapidly. The number of longevity-focused biotech companies surged from 50 in 2015 to over 250 by 2024, a fivefold increase in less than a decade. Currently, more than 65 anti-aging therapeutics are in development worldwide, spanning biologics and small molecules across different clinical phases. The sector now encompasses over 814 companies that have closed 2,261 funding rounds from 1,900+ investors.

The anti-aging sector employs over 381,000 professionals worldwide, having added 30,400 new jobs in the past year alone.

Innovation hubs are concentrated in the USA, India, UK, Germany, and Canada, with key cities including New York, London, Singapore, New Delhi, and Sydney.

Longevity Funding Trends: 2015-2024



Longevity sector funding demonstrates volatile growth patterns over the past decade. Starting from \$984K across 10 rounds in 2015, funding surged to \$162M in 2016, marking early investor enthusiasm. The sector experienced fluctuation through 2017-2019 (\$48.7M-\$73.6M), followed by a breakout \$130M in 2020 reflecting pandemic-driven health technology interest.

Post-pandemic years showed inconsistency: declining to \$46.8M in 2021, recovering to \$60.7M in 2022, then collapsing to \$9.64M in 2023—the lowest since 2017, indicating sector correction amid broader tech downturn. 2024 marks resurgence with \$64.4M across 21 rounds—the highest deal count ever recorded, suggesting renewed investor confidence through increased early-stage activity despite modest capital deployment. This reflects maturation from mega-rounds toward diversified portfolio approaches.

MAJOR PLAYERS AND LANDMARK DEALS:

ALTOS LABS



Altos Labs stands as the most heavily funded longevity startup, having raised \$3.3 billion with backing from Jeff Bezos and Yuri Milner. The company's valuation reached \$6.33 billion as of February 2024. Altos focuses on cellular rejuvenation programming to restore cell health and resilience.

BIOAGE LABS



BioAge Labs completed the largest longevity IPO of 2024, raising \$198 million at \$18 per share when it went public on NASDAQ in September. The company's lead candidate azelaprag targets metabolic diseases through aging biology, with trials combining it with GLP-1 drugs like Zepbound.

RETRO BIOSCIENCES



Retro Biosciences, backed entirely by OpenAI CEO Sam Altman with an initial \$180 million seed round, is now raising a \$1 billion Series A. The company aims to extend healthy human lifespan by 10 years through three parallel approaches: cellular reprogramming, autophagy enhancement, and plasma-inspired therapies.

NEWLIMIT



NewLimit, co-founded by Coinbase CEO Brian Armstrong, raised \$130 million in Series B led by Kleiner Perkins in May 2025, followed by an additional \$45 million including investment from Eli Lilly. The company's valuation reached \$810 million, with a subsequent raise reportedly valuing it at \$1.62 billion.

LIFE BIOSCIENCES



Life Biosciences raised \$82 million in Series C funding led by Alpha Wave Ventures in 2022, bringing total funding to over \$158 million. The company develops therapeutics across three platforms targeting mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming.

INSILICO MEDICINE



Insilico
Medicine

Insilico Medicine raised \$95 million in Series D funding (total \$130 million in the round), with the company developing AI-driven drug discovery platforms for longevity therapeutics. Insilico has advanced multiple drug candidates to clinical trials using generative AI.

INDIAN VIEW: INDIA'S EMERGING LONGEVITY ECOSYSTEM

INDIAN LONGEVITY FUNDING: 2016-2025 OVERVIEW

India's longevity and anti-ageing startup funding ecosystem remains nascent and highly sporadic, demonstrating minimal institutional capital deployment compared to global markets. Total disclosed funding from 2016-2025 amounts to approximately \$50.1M across 12 funding rounds—a stark contrast to the global longevity sector's multi-billion dollar investments.

2022 marked the peak year with \$6.54M, driven by growing awareness of healthtech opportunities. 2025 shows momentum with \$10M, indicating accelerating investor interest in India's emerging longevity space

Critical funding gaps exist: 2017 and 2019 recorded zero activity, reflecting limited venture capital focus on aging sciences during those periods.

Despite possessing 150+ million seniors, India attracts minimal longevity investment versus developed markets, presenting extraordinary opportunity for capital deployment in underserved markets.

TOP 5 INDIAN LONGEVITY STARTUPS - CONDENSED OVERVIEW

BIOPEAK



FOUNDED YEAR: 2024



BENGALURU



\$6.5M

BIOPEAK
LIMITLESS LIVING

Investors: Claypond Capital, Prashanth Prakash, Nikhil Kamath

India's first dedicated longevity clinic targeting athletes and patients with complex chronic conditions. Combines 130+ biomarkers, advanced imaging, and AI-driven diagnostics with six-hour multidisciplinary consultations. Partnerships with IISc and Longevity India enable South Asian protocol adaptation. Expanding to Mumbai, Delhi, Hyderabad, Pune.

CONTINUE RESEARCH (DEEPINDER GOYAL INITIATIVE)



FOUNDED YEAR: 2023



\$25M PERSONAL COMMITMENT

Type: Open-source research collective

Zomato founder Deepinder Goyal's pioneering longevity fund investigating upstream aging mechanisms through two grant tracks: Moonshots (\$50K-\$250K) and Deep Dives (\$250K-\$2M). All findings are open-source. Aligns with India's ₹1 lakh crore R&D corpus for pre-commercial science.

ADVANCEXO



FOUNDED YEAR: 2023



NOIDA

Parent: Advancells Group

India's only dedicated exosome manufacturer supplying MSC-derived exosomes to dermatology clinics for anti-aging, skin rejuvenation, and hair loss. B2B model with GMP-certified production and LC-MS validation. Leverages Wharton's Jelly stem cells for maximum regenerative potency.

BETTERHOOD



BENGALURU

CUSTOMER BASE: 20,000+

Musculoskeletal wellness ecosystem combining orthopedic products, digital diagnostics, and longevity goal-setting. The "Centenarian Challenge" framework defines users' 80-year lifestyle goals, determining current health targets. Addresses India's rising back pain disability through integrated physical products and content education

ELIXIR WELLNESS



FOUNDED YEAR: 2021



MUMBAI (EXPANDING)

Premium medical wellness brand integrating biohacking, regenerative medicine, and AI-diagnostics. Combines cryotherapy, PRP/stem cell therapies, and personalized protocols as "luxury rituals." Expanding to Delhi, Bangalore, Ahmedabad targeting affluent consumers seeking Science-backed preventive healthcare.



Home care products maker Happi Planet raises \$2 Mn:

Mumbai-based **Happi Planet**, a home care products maker, has raised **\$2 million (₹18 crore)** in its **first institutional funding round** led by **Fireside Ventures** and **Prath Ventures**. Founded in **2021**, the startup offers **eco-friendly home care products** including laundry, dishwashing, and surface cleaners. The funds will help expand its **product range, distribution, operations, and team**. Happi Planet sells via **D2C channels, online marketplaces, and select offline stores**, targeting urban households. It competes with brands like **Neynto, Beco, The Better Home, Godrej Consumer Products, HUL, and ITC**.



Fambo raises Rs 21.55 Cr Series A round led by AgriSURE Fund

Noida-based **Fambo** raised **₹21.55 crore** in a **Series A** round led by **AgriSURE Fund** and **EV2 Ventures**. Founded in **2022**, it supplies **fresh and semi-processed food** to **1,000+ restaurants** like McDonald's and Barbeque Nation. Funds will boost **expansion, product diversification, tech upgrades, and strengthen its AI-enabled, temperature-controlled supply chain**.



Smallest.ai raises \$8 Mn in seed funding led by Sierra Ventures

Smallest.ai, a San Francisco and Bengaluru-based **Enterprise Voice AI platform**, raised **\$8 million** in seed funding led by **Sierra Ventures**, with **3one4 Capital** and **Better Capital**. Founded by **Sudarshan Kamath** and **Akshat Mandloi**, it will use funds to **expand globally, enhance its AI voice automation stack, and drive enterprise adoption**.




Performance nutrition brand Neulife raises \$1 Mn in seed round

Mumbai-based **Neulife** raised **\$1 million** in **seed funding** co-led by **Subhkam Ventures** and **Singularity Ventures**, with **Sunicon** and **Cosma Ventures** participating. Founded in **2014**, the **R&D-led performance nutrition brand** will use funds to **develop new products, expand research, scale protein offerings, and accelerate global expansion**.



Fragaria Fruits raises \$2 Mn in seed round led by WEH Ventures

Chennai-based **Fragaria Fruits** raised **\$2 million** in **seed funding** led by **WEH Ventures**, with **Rainmatter, Spiral Ventures**, and angels participating. Founded in **2024**, it grows **premium, pesticide-free fruits** using **vertical farming**. Funds will **scale Bengaluru operations, expand into blueberries and raspberries, and strengthen sustainable, year-round production**.



LONGEVITY INDUSTRY 1.0

DEFINING THE BIGGEST AND MOST COMPLEX INDUSTRY IN HUMAN HISTORY BY DMITRY KAMINSKIY

In a world where technology and science are reshaping every aspect of human life, the **quest for longevity** has emerged as one of the most exciting frontiers of innovation. Dmitry Kaminskiy's *Longevity Industry 1.0* offers a comprehensive look at how humanity's age-old desire to live longer, healthier lives is evolving into a structured, trillion-dollar global industry — what he calls the **Longevity Economy**.

Kaminskiy, a futurist and investor deeply embedded in the biotech and AI ecosystem, unpacks how **advancements in artificial intelligence, deep data analytics, regenerative medicine, and precision healthcare** are transforming the fight against ageing. Rather than treating ageing as an inevitable decline, the book positions it as a **manageable and measurable condition** — one that can be delayed, optimized, and eventually, potentially reversed.

The book outlines how the longevity sector is not limited to healthcare or pharmaceuticals. It spans **biotech startups, AI-driven diagnostics, nutrition, wellness, mental health, wearable tech, and even financial models** that support longer living populations. Kaminskiy argues that the convergence of these fields has created one of the most complex yet promising industries of the 21st century — one that will redefine how governments, investors, and consumers think about health, productivity, and ageing.

What sets *Longevity Industry 1.0* apart is its industry-mapping approach. Kaminskiy doesn't just present scientific progress — he charts out the economic, technological, and policy frameworks that are shaping the future of longevity. The book also highlights how regions like the US, UK, Switzerland, Singapore, and Israel are building specialized ecosystems for longevity research and investment, creating a global race toward healthier, longer lifespans.

For startup founders and investors, the book is a treasure trove of insights. It encourages entrepreneurs to see longevity not as a niche healthcare segment but as a transformational business opportunity. From AI-powered biomarkers to personalized nutrition and cognitive health platforms, Kaminskiy identifies where innovation can create the next generation of high-impact companies.

In essence, *Longevity Industry 1.0* is both a wake-up call and a roadmap. It urges readers to view ageing not as a biological limitation, but as the next great economic and scientific revolution. Visionary, data-rich, and deeply thought-provoking, it's a must-read for anyone interested in the intersection of technology, science, and the future of human healthspan.

TERMINOLOGIES



AI-driven Diagnostics:

Artificial intelligence used to detect diseases early and predict ageing-related risks

Digital Biomarkers:

Health indicators collected through wearables or sensors that track biological changes.



Biogerontology:

A field of science focusing on the biological processes of ageing.

Regenerative Medicine:

Techniques that repair or replace damaged cells, tissues, or organs.



Gene Therapy:

A technique that modifies a person's genes to treat or prevent disease.



**Global angel investment platform,
empowering startups by providing growth capital and connect.**

FOR STARTUPS

To raise funds from UNISYNC,
please submit your details at
<https://bit.ly/UnisyncStartup>

FOR INVESTORS

To become UNISYNC ANGEL,
please submit your details at
<https://bit.ly/UnisyncInvestor>

OUR PRESENCE

INDIA: Mumbai | Delhi | Bangalore | Ahmedabad | Surat
INTERNATIONAL: Singapore | Dubai | London | San Jose

FOR MORE DETAILS, REACH OUT TO US:

Unisync Angels Private Limited

1st Floor Provyz, B-wing SNS Atria
Opp. Jolly Party Plot, Vesu, Surat

+91 95126 67000 | contact@unisyncangels.com
www.unisyncangels.com